- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
North Chicago Today
By the People, for the People
NorthRock Partners LLC Increases AbbVie Inc. Stock Position
Investment firm adds over 6,000 shares to its AbbVie holdings in Q3 2025
Mar. 14, 2026 at 10:18am
Got story updates? Submit your updates here. ›
NorthRock Partners LLC, an investment management firm, increased its position in AbbVie Inc. (NYSE: ABBV) by 8.2% in the third quarter of 2025, according to a recent filing with the Securities and Exchange Commission. The firm now owns 83,067 shares of the pharmaceutical company's stock, valued at $19.23 million.
Why it matters
AbbVie is a major pharmaceutical company with a diverse product portfolio, including immunology, oncology, and women's health treatments. Institutional investors' holdings in the stock can provide insights into market sentiment and expectations around the company's future performance.
The details
NorthRock Partners LLC added 6,270 shares of AbbVie to its portfolio during the third quarter, bringing its total position to 83,067 shares. The investment firm's holdings in AbbVie are now valued at $19.23 million. AbbVie's stock price has fluctuated in recent quarters, with the company facing competition and regulatory challenges for some of its key products.
- NorthRock Partners LLC increased its AbbVie position in the third quarter of 2025.
The players
NorthRock Partners LLC
An investment management firm that increased its position in AbbVie Inc. by 8.2% in the third quarter of 2025.
AbbVie Inc.
A global biopharmaceutical company that focuses on developing and commercializing therapies for complex and chronic medical conditions.
The takeaway
The increase in NorthRock Partners' AbbVie holdings suggests the investment firm sees potential in the pharmaceutical company's long-term growth prospects, despite near-term challenges. As a major player in the industry, AbbVie's performance and market positioning will continue to be closely watched by investors and analysts.
